Bispecific MASP-2/3 antibody provides superior renoprotection over monotherapy in pristane-induced lupus nephritis
Clinical and Experimental Immunology · 06.01.2026 · 220 (1)
DOI: 10.1093/cei/uxag031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 29.05.2026. Verfasst von Tianqi Tu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: Lupus Nephritis, Mannose-Binding Protein-Associated Serine Proteases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Beijing Natural Science Foundation, Capital's Funds for Health Improvement and Research, National Key Research and Development Program of China.
Abstract (Originalsprache)
Lupus nephritis (LN) is a major cause of organ damage in systemic lupus erythematosus and is driven in part by overactivation of the lectin pathway (LP) and alternative pathway (AP) of complement. Mannan-binding lectin-associated serine protease-2 (MASP-2) initiates LP through C4/C2 cleavage, whereas MASP-3 enables AP amplification by activating pro-factor D. We hypothesized that concurrent inhibition of both proteases would provide superior renoprotection compared with single-pathway blockade in established disease. Female BALB/c mice with pristane-induced LN received anti-MASP-2, anti-MASP-3, bispecific antibodies, or vehicle for 4 weeks. Bispecific MASP-2/3 inhibition produced greater improvements in albuminuria, renal activity index, and glomerular C3d and C5b-9 deposition than either monotherapy. Functional assays confirmed selective LP suppression with MASP-2 blockade and AP suppression with MASP-3 blockade, whereas dual inhibition maximally reduced both pathways and their downstream complement effectors. Kidney transcriptomics demonstrated broad down-regulation of complement, coagulation, and inflammatory gene networks. Together, these findings indicate that bispecific MASP-2/3 blockade provides robust complement-directed protection in established LN and may represent an effective therapeutic strategy for complement-mediated kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, China.
- Institute of Nephrology, Peking University, Beijing 100034, China.
- Key Laboratory of Renal Disease, Ministry of Health of China, Beijing 100034, China.
- Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing 100034, China.
- Staidson (Beijing) Biopharmaceuticals Co., Ltd, Beijing 100176, China.
Förderung
- Beijing Natural Science Foundation
- Capital's Funds for Health Improvement and Research
- National Key Research and Development Program of China
- National High Level Hospital Clinical Research Funding
- CAMS Innovation Fund for Medical Sciences
- Peking University First Hospital
Zitieren
APA
Tu, T., Wang, C., Li, Z., Fu, W., Tan, Y., & Zhao, M. (2026). Bispecific MASP-2/3 antibody provides superior renoprotection over monotherapy in pristane-induced lupus nephritis. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag031
Vancouver
Tu T, Wang C, Li Z, Fu W, Tan Y, Zhao M. Bispecific MASP-2/3 antibody provides superior renoprotection over monotherapy in pristane-induced lupus nephritis. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag031
BibTeX
@article{Tu2026,
author = {Tu, Tianqi and Wang, Chuqiao and Li, Zhong and Fu, Wenyan and Tan, Ying and Zhao, Minghui},
title = {Bispecific MASP-2/3 antibody provides superior renoprotection over monotherapy in pristane-induced lupus nephritis},
journal = {Clinical and Experimental Immunology},
year = {2026},
volume = {220},
number = {1},
doi = {10.1093/cei/uxag031}
}
EUVIMED